PER-014-98
Completed
未知
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C USING ALFA 2B INTERFERON ASSOCIATED WITH RIBAVIRINE, COMPARING IT WITH THE SAME SCHEME PREVIOUS FROM DAILY ADMINISTRATION FOR 2 WEEKS OF ALFA 2 B INTERFERO
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- SCHERING PLOUGH RESEARCH INSTITUTE,
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (HCC) USING PEG-INTERFERON ALPHA 2B AND RIBAVIRINEPER-039-01SCHERING PLOUGH RESEARCH INSTITUTE,
Completed
Not Applicable
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B (HCB) USING PEG-INTERFERON ALPHA 2BPER-040-01SCHERING PLOUGH RESEARCH INSTITUTE,
Not yet recruiting
Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects with Chronic Hepatitis BACTRN12614000628640Gilead Sciences, Inc.150
Completed
Phase 2
Study of new therapy in patients with chronic hepatitis C including liver cirrhosischronic hepatitis C and liver cirrhosisJPRN-UMIN000008289niversity of Tsukuba10
Not yet recruiting
Not Applicable
Systemic therapy for Unresectable Hepatocellular Carcinoma: Therapeutic Effectiveness by Treatment Modality and Optimal Drug Use Ordernresectable hepatocellular carcinomaJPRN-UMIN000051797Japanese Red Cross Society Himeji Hospital5,000